‘We are confident inside our sNDA submission and appearance forward to talking about the efficacy and security data for VIVITROL for opioid dependence with the people of the panel and the FDA review team. If approved, VIVITROL could change the procedure paradigm as the initial and only non-narcotic, nonaddictive, once-monthly medication for the treatment of opioid dependence.in April 2010 ‘ Alkermes submitted the sNDA for VIVITROL for opioid dependence. Confirmation and information on the FDA advisory committee conference for VIVITROL are expected to be released in the Government Register about six to eight weeks before the scheduled meeting time.They were treated at 1 of 2 academic centers that offer equal access to treatment in the populace. African-American patients were more likely to present with favorable disease staging, with just 33 percent presenting with stage III or more, weighed against 50 percent of non-African Americans. However, African-American patients waited longer from diagnosis to begin with treatment than non-African-American individuals significantly, at a median of 45 days weighed against 35 days. In addition they waited significantly much longer between completing chemoradiotherapy and going through surgery.